• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Nipro’s Infraredx wins expanded FDA nod for Makoto intravascular imager

Nipro’s Infraredx wins expanded FDA nod for Makoto intravascular imager

April 22, 2019 By Fink Densford

Nipro's Infraredx

Nipro (TYO: 8086) subsidiary Infraredx said today that it won expanded FDA 510(k) clearance for its Makoto intravascular imaging system, now cleared to identify patients and coronary plaques at an increased risk of major adverse cardiac events.

The approval came based on results from the Lipid-Rich Plaque study in which researchers explored the ability of intravascular ultrasound and near-infrared spectroscopy technology to identify patients and coronary plaques at an increased risk for MACE, the Burlington, Mass.-based company said.

“We are very proud of this new milestone that expands the indication for use of the Makoto Imaging System and accompanying Dualpro IVUS+NIRS catheter to detect both plaques and patients at high risk for dangerous cardiovascular events. IVUS+NIRS imaging has the power to transform the imaging world as we know it and we hope that its use will help predict and prevent heart attacks,” Infraredx prez & CEO Nozomu Fujita said in a prepared statement.

Data in the study came from 1,563 patients from 44 sites across the U.S. and Europe, and used IVUS+NIRS technology to assess patient and plaque lipid core burden index (LCBI) in both stable and unstable patients requiring and angiogram procedure for new or ongoing cardiac symptoms, Infraredx said.

Results from the trial indicated that patients with a maxLCBI4mm, the term for the max value of any 4mm section, of 400 were at 87% higher risk of non-index culprit lesion related MACE than a patient with a lesser maxLCBI4mm. Results also indicated that the risk of non-index culprit lesion related MACE in a coronary segment with a maxLCBI4mm greater than 400 was more than four times greater than in a segment with lesser maxLCBI4mm.

“These expanded FDA label claims are evidence based on the NIRS imaging technology that was demonstrated in the landmark Lipid-Rich Plaque Study. The study demonstrated that NIRS imaging can identify both patients and non-culprit lesions at risk for subsequent events. These label claims are an important and exciting milestone for the technology and the physicians who have access to the NIRS technology. This carries important information for patients and physicians,” principal investigator Dr. Ron Waksman of the MedStar Heart Institute said in a prepared release.

Last September, Infraredx released results from a study of its intravascular ultrasound and near-infrared spectroscopy technology platforms, touting their ability to identify patients and coronary plaques as vulnerable to future major adverse cardiovascular events, including heart attacks.

Filed Under: 510(k), Food & Drug Administration (FDA), Imaging, Regulatory/Compliance, Vascular Tagged With: InfraReDx Inc., Nipro

More recent news

  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Preceptis Medical has a new CEO as it advances ear tube tech
  • FDA clears first over-the-counter cuffless blood pressure monitor
  • Mendaera wins FDA clearance for robotic needle placement
  • Johnson & Johnson seeks to have $442 million antitrust verdict tossed out

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy